Normal Cranial Nerves in the Cavernous Sinuses: Contrast-Enhanced Three-Dimensional Constructive Interference in the Steady State MR Imaging

Akiko Yagi, Noriko Sato, Ayako Taketomi, Takahito Nakajima, Hideo Morita, Yoshinori Koyama, Jun Aoki, and Keigo Endo

BACKGROUND AND PURPOSE: Three-dimensional (3D) constructive interference in steady state (CISS) MR imaging is useful for demonstrating cranial nerves (CNs) in the cistern. The purpose of this study was to evaluate normal CNs III, IV, V₁, V₂, and VI in the cavernous sinuses by using contrast-enhanced, three-dimensional (3D), Fourier transformation CISS MR imaging.

METHODS: In 76 normal cavernous sinuses from 38 patients, detectability of CNs III–VI in the bilateral cavernous sinuses was evaluated by using contrast-enhanced 3D CISS MR imaging. In 40 cavernous sinuses from 20 patients, contrast-enhanced 3D CISS and contrast-enhanced T1-weighted MR imaging were compared for the detectability of these CNs.

RESULTS: Each CN was separately demonstrated, and in 11 patients (29%), all CNs in the cavernous sinuses were identified on contrast-enhanced 3D CISS MR imaging. The images depicted the intracavernous segments of CNs III, IV, V₁, V₂, and VI in 76 (100%), 46 (61%), 70 (92%), 67 (88%), and 73 (96%) of the 76 sinuses, respectively. In comparison of imaging techniques, contrast-enhanced 3D CISS MR imaging had a detection rate significantly higher than that of enhanced T1-weighting imaging (P < .05) in all CNs except for CN III, which was detected in 100% of cases with both techniques.

CONCLUSION: Contrast-enhanced 3D CISS MR imaging provides clear images of each CN in the cavernous segment. This useful method may contribute to the diagnosis of diseases involving the cavernous sinuses, such as Tolosa-Hunt syndrome.

The cavernous sinus contains the venous plexus, internal carotid artery (ICA), periartrial sympathetic nerve fibers, fibrous tissue and cranial nerves (CNs) III (oculomotor nerve), IV (trochlear nerve), V₁ (ophthalmic nerve), V₂ (maxillary nerve), and VI (abducens nerve). Given the inclusion of these major vessels and nerves, the cavernous sinus is a clinically important structure. Visualization of CNs III, IV, V₁, V₂, and VI in the cavernous sinus has been reported with both MR imaging and CT (1–8). However, precise evaluation of these CNs in the cavernous sinus is difficult.

Three-dimensional (3D) constructive interference in steady state (CISS) is a high spatial–resolution, refocused, gradient-echo sequence that is flow compensated. The 3D CISS sequence depicts small structures surrounded by CSF with high contrast and high spatial resolution; therefore, it is suitable for depicting CNs in the cistern. 3D CISS gives the appearance of a heavily T2-weighted sequence. Because the contrast of CISS sequence is proportional to T2 relaxation time/T1 relaxation time, CSF signal intensity on CISS imaging is higher than that of brain parenchyma. Therefore, CISS images have an appearance similar to that of T2-weighted images. However, 3D CISS sequences show increased contrast as concentration of gadolinium-based contrast agent increases (9). We found that CNs III, IV, V₁, V₂, and VI in the cavernous sinus were well demonstrated in vivo on 3D CISS imaging after the injection of gadodiamide hydrate, with the well-enhanced venous plexus of the cavernous sinus playing a similar role to CSF. Using this new method, we studied the normal anatomy in...
the cavernous sinus and evaluated the detectability of each CN on both contrast-enhanced 3D CISS MR imaging and contrast-enhanced conventional T1-weighted MR imaging.

**Methods**

**Patients**

Detectability of intracavernous segments of CNs III, IV, V₁, V₂, and VI was evaluated on MR imaging in 76 normal cavernous sinuses. We examined 38 patients (13 men, 25 women; mean age, 51.2 years; range, 16–78 years) between June 2000 and April 2004. Their presentations and indications included acoustic schwannoma (n = 11); cholesteatoma (n = 4); screening for brain metastases in patients with thoracic or abdominal malignancies without other known metastasis (n = 5); benign nasal tumor (fibroma and schwannoma, n = 2); neurovascular compression of a facial nerve (n = 3); Rathke cleft cyst (n = 2); temporal bone cyst (n = 1); middle ear adenoma (n = 1); pineal cyst (n = 1); pituitary screening (n = 2); and screening for auditory disturbance, tinnitus, or dizziness (n = 6). All patients were free of neurologic symptoms for CNs III–VI and had not received chemotherapy or radiation therapy. No patients had paranasal sinusitis. Eleven patients with acoustic schwannoma had undergone surgical resection 3–24 months earlier, without recurrence. Tumor size before surgery was <10 mm in all 11 patients and did not involve CNs III–VI. Two patients who underwent pituitary screening had no abnormal MR findings. One was referred for an evaluation of an elevated serum thyroid stimulating hormone level due to antithyroid medication, and the other patient was referred for an evaluation of obesity. All patients being screened for auditory disturbance or tinnitus or dizziness had normal MR imaging results. All participants provided written informed consent before entering the study.

**MR Imaging**

All MR imaging examinations were performed by using a 1.5-T unit (Magnetom Symphony; Siemens, Erlangen, Germany) with a regular head coil. All patients underwent contrast-enhanced 3D CISS MR imaging for the evaluation of bilateral cavernous sinuses. Gadodiamide hydrate (Omniscan; Daiichi Pharmaceutical Co., Tokyo, Japan) was administered at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent. In addition, 20 patients underwent contrast-enhanced 3D CISS MR imaging at a dose of 0.1 mmol/kg body weight as the intravenous contrast agent.

**Image Analysis**

Data obtained by using 3D CISS MR imaging were reconstructed in coronal planes by using a section thickness of 0.7 mm. Images were analyzed with a multiplanar reconstruction program (Siemens). We compared the position of a given point in one plane with the same position in two other perpendicular planes. Two neuroradiologists (A.Y., N.S.) analyzed the images collaboratively. Each neuroradiologist made initial evaluations independently, and any disagreements regarding final conclusions were resolved by consensus. Normal CNs III–VI were identified in the cavernous sinus when a dark spot was observed in the appropriate location on more than three consecutive sections from contrast-enhanced CISS MR imaging and on more than one section from contrast-enhanced T1-weighted MR imaging. In addition, we confirmed the continuity of each nerve on reconstructed planes by following the course of each nerve to exclude false-positive results. When CNs were not identified, they were defined as not identified.

In 76 normal cavernous sinuses from 38 patients, detectability of intracavernous segments of CNs III–VI was examined by using contrast-enhanced 3D CISS MR imaging. To evaluate the influence of age, comparisons were made between two groups: those younger than 55 years and those older than 55 years. In 40 cavernous sinuses from 20 patients, the detectability of CNs III–VI was compared between contrast-enhanced CISS MR imaging and contrast-enhanced T1-weighted MR imaging.

**Statistical Analysis**

Statistical comparison of the detectability of CNs with both imaging techniques was performed by using the Fischer exact probability test. Statistical comparison of the detectability of CNs III–VI on contrast-enhanced 3D CISS MR imaging between the two age groups was also performed by using the Fischer exact probability test. P < .05 was considered to indicate a statistically significant correlation.

**Results**

Intracavernous segments of CNs III, IV, V₁, V₂, and VI were identified on contrast-enhanced 3D CISS MR imaging in 76 (100%), 46 (61%), 70 (92%), 67 (88%), and 73 (96%) of the 76 cavernous sinuses, respectively. In 11(29%) of 38 patients, all CNs in the cavernous sinus were identified (Fig 1). No significant differences in each nerve were observed between the younger group (six men, 13 women; age ≤ 55; mean age, 37.4 years) and the older group (seven men, 12 women; age >55 years; mean age, 64.9 years) (Table 1).

Our comparison of the detectability of the 40 cavernous sinuses showed that intracavernous segments of CNs III, IV, V₁, V₂, and VI were identified in 40 (100%), 26 (65%), 37 (93%), 35 (88%), and 38 (95%) cases on contrast-enhanced 3D CISS MR imaging, and in 40 (100%), 12 (30%), 18 (45%), 21 (53%), and 26 (65%) cases on contrast-enhanced T1-weighted MR imaging, respectively (Table 2). CN III was identified in all cases on both contrast-enhanced 3D CISS and contrast-enhanced T1-weighted MR imaging. However, significant differences were noted in all other CNs between the two imaging techniques. Enhanced 3D CISS MR imaging was superior to enhanced T1-weighted MR imaging in depicting the CNs in the cavernous portions (Fig 2).

**Discussion**

The anatomy of the cavernous sinus has been studied on dissections and is well explored (10–17). CN III lies superolateral to the ICA, and CN IV is inferior to CN III. CN V₁ courses inferolateral to the upper portion of the ICA siphon, and CN V₂ runs in the inferolateral aspect of the cavernous sinus. CN VI is the only CN to run inside the cavernous sinus, lateral to the ICA.

Some groups have reported cavernous sinus structures on MR imaging (1–4, 18). One of them evaluated the detectability of CNs in the normal cavernous sinus.
Fig. 1. Contrast-enhanced CISS MR images (TR/TE = 11.8/5.9) in a 44-year-old woman whose acoustic schwannoma had been resected without recurrence.

A. Coronal view clearly shows bilateral CNs III (long black arrow), IV (black arrowhead), V1 (long white arrow), V2 (white arrowhead), and VI (short black arrow) are clearly demonstrated in the normal cavernous sinuses. Additional dark spot is shown inferior to left CNs V1 and VI (short white arrow).

B. Oblique sagittal view also depicts the left CNs III (long black arrow) and VI (short black arrow) well. Additional dark region shown in A is also identified as a serpiginous, dark line without continuity (short white arrow). It is considered to be fibrous tissue.

### TABLE 1: Detectability of cranial nerves in patients with normal cavernous sinuses on enhanced 3D CISS MR imaging

<table>
<thead>
<tr>
<th>Patients</th>
<th>CN</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>16–55 y (n = 38)*</td>
<td>III</td>
<td>38 (100)</td>
<td>24 (63)</td>
<td>36 (95)</td>
</tr>
<tr>
<td>56–78 y (n = 38)†</td>
<td>IV</td>
<td>38 (100)</td>
<td>22 (58)</td>
<td>34 (89)</td>
</tr>
<tr>
<td></td>
<td>V1</td>
<td>38 (100)</td>
<td>22 (58)</td>
<td>34 (89)</td>
</tr>
<tr>
<td></td>
<td>V2</td>
<td>38 (100)</td>
<td>22 (58)</td>
<td>34 (89)</td>
</tr>
<tr>
<td></td>
<td>VI</td>
<td>38 (100)</td>
<td>22 (58)</td>
<td>34 (89)</td>
</tr>
</tbody>
</table>

Note.—Data are the number of nerves identified. Data in parentheses are percentages.

* Mean age, 37.4 y.
† Mean age, 64.9 y.

### TABLE 2: Detectability of cavernous segments of cranial nerves in 40 normal cavernous sinuses on enhanced imaging

<table>
<thead>
<tr>
<th>Contrast-Enhanced Imaging</th>
<th>CN</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CISS (n = 40)</td>
<td>III</td>
<td>40 (100)</td>
<td>26 (65)</td>
<td>37 (93)</td>
</tr>
<tr>
<td>T1 weighted (n = 40)</td>
<td>IV</td>
<td>40 (100)</td>
<td>12 (30)</td>
<td>18 (45)</td>
</tr>
</tbody>
</table>

P value .003 .001 .001 .001

Note.—Data are the number of nerves identified. Data in parentheses are percentages.

sinuses. Korogi et al (4) studied dynamic contrast-enhanced MR imaging of the cavernous sinus. In their study, CNs III and IV were defined as a single anatomic structure, as were V1 and VI. On dynamic MR imaging, CNs III and IV, V1 and VI, and V2 all had a detectability rate of 75%. On conventional contrast-enhanced MR imaging, the detectability rates were 62%, 30%, and 28%, respectively. We believe that CN V1 and VI should be distinguished, even on contrast-enhanced T1-weighted MR imaging, because their anatomic courses in the cavernous sinus differ, as we have shown. To our knowledge, no imaging study has been undertaken to precisely evaluate the CNs in the cavernous sinus in vivo, and we may be the first to demonstrate them clearly and separately.

Casselman et al (19) introduced the 3D CISS sequence to visualize CNs in the internal acoustic canal and at the cerebellopontine angle. The 3D CISS sequence has been used to demonstrate various other CNs (20–27). Yousry et al (22) used the 3D CISS sequence to show that 11 of the 12 CNs in their cisternal course were always (100%) identified with a high degree of certainty, with only CN IV varying in cisternal course and being identified in just 47.5% of cases.

To our knowledge, no studies have demonstrated CNs III–VI in the cavernous sinus on CISS MR imaging. Shigematsu et al (9) reported that, although 3D CISS gives the appearance of a heavily T2-weighted sequence, 3D CISS sequences show increased contrast as concentration of gadolinium-based contrast agent increases. Our study showed that CNs III, IV, V1, V2, and VI in the cavernous sinus were well visualized on contrast-enhanced 3D CISS MR imaging, with the enhanced venous plexus playing a role similar to CSF. Venous spaces in the cavernous sinus were strongly enhancing, and CNs were shown as nonenhanced spots of hypointensity. In a previous study, it was not possible to detect each CN separately. On the contrary, we visualized each nerve clearly for the first time. Detectability rates for CNs III, IV, V1, V2, and VI in the cavernous sinus were 100%, 61%, 92%, 88%, and 96%, respectively, on contrast-enhanced CISS MR imaging. These detectability rates are higher than those of the previous
We compared detectability between contrast-enhanced CISS and contrast-enhanced T1-weighted MR imaging and found that it was predominantly and significantly higher with the former than with the latter.

CN III is large and was identified on both contrast-enhanced CISS and contrast-enhanced T1-weighted MR imaging at a rate of 100%. In a previous report, CN IV in the cavernous sinus could not be individually discriminated because of its small size and proximity to CN III (18). However, contrast-enhanced CISS MR imaging depicted CN IV in 61% of cases. We found that CN IV did not always run near CN III and sometimes ran near CN V1. van Overbeeke et al (16) reported that, in 75% of their dissections, CN IV was near to CN III; in the other 25%, the nerve was closer to CN V1. Detectability of CNs V1 and V2 was high in our study. V3 was reportedly easy to identify during routine head MR imaging, given its exit from the skull through the foramen rotundum (18). Indeed, in our study, V2 was easily identified. However, when it was flattened and tightly attached to the dura matter, its differentiation from dura was sometimes difficult. CN VI was second only to CN III in terms of detectability, because of its characteristic course inside the cavernous sinus.

On contrast-enhanced CISS MR imaging, some nonenhanced areas were observed in addition to CNs. These were considered to correspond to periarterial sympathetic fibers, fibrous tissues, or branches of the ICA. From the intracavernous segment of the ICA, two main branches arise, the meningohypophyseal trunk and the inferior lateral trunk. The three main branches of the meningohypophyseal trunk are the tentorial artery, the dorsal meningeal artery, and the inferior hypophyseal artery (10). Branches of CN VI were also considered responsible for some nonenhanced structures. Harris and Rhoton (10) found that the abducens nerve does not always represent a single trunk in the cavernous sinus, and it frequently splits.
into multiple rootlets numbering anywhere from two to five. Ozveren et al (28) stated that, in autopsy materials, four of 50 cases had a duplicated bilateral abducens nerves, and seven of 50 cases had duplicated unilateral abducens nerves. We distinguished the CNs from other structure on the oblique view that was reconstructed during 3D CISS MR imaging (eg, Fig 1B).

Conclusion

Contrast-enhanced 3D CISS MR imaging offers clear images of normal CNs in the cavernous sinus, which has not been shown in vivo. In the comparative study between contrast-enhanced CISS and contrast-enhanced T1-weighted MR imaging, the former offered significantly higher detectability of CNs. Contrast-enhanced 3D CISS MR imaging is a useful method, one that will contribute to the diagnosis of diseases involving cavernous sinuses, such as Tolosa-Hunt syndrome.

Acknowledgments

We thank Kazuo Takeuchi, MD, MPH, PhD, from Takasaki University of Health and Welfare, for his support in the statistical analysis in the present study.

References